Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.41 |
| ▸ | BCL2 | P10415 | 3/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.41 |
| ▸ | NT5E | P21589 | 5/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | MAT2A | P31153 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22071831 | 0.91 | BCL2 (0.44) | MCL1BCL2MDM2NT5EFGFR1 | |
| SCHEMBL22071834 | 0.89 | PTGES (0.44) | MCL1BCL2MDM2NT5EPRMT1 | |
| SCHEMBL21449912 | 0.89 | MDM2 (0.42) | MCL1BCL2MDM2PTGES | |
| SCHEMBL21449914 | 0.85 | GRM1 (0.40) | MCL1BCL2MDM2NT5EPTGES | |
| SCHEMBL19781603 | 0.85 | PRMT1 (0.39) | MCL1BCL2MDM2PRMT1FGFR1 | |
| SCHEMBL22071828 | 0.84 | NT5E (0.39) | MCL1BCL2MDM2NT5EPTGES | |
| SCHEMBL19781136 | 0.82 | BCL2 (0.38) | MCL1BCL2MDM2PRMT1FGFR1 | |
| SCHEMBL22071851 | 0.81 | MAP4K4 (0.39) | MCL1BCL2MDM2PRMT1FGFR1 | |
| SCHEMBL22071847 | 0.81 | PRKAB2 (0.42) | MCL1BCL2MDM2NT5EPRMT1 | |
| SCHEMBL22071833 | 0.81 | PRMT1 (0.38) | MCL1BCL2MDM2PRMT1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193038-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | ARISAN THERAPEUTICS INC. (US) | 2022-06-07 | — | — | US | disclosed |
| WO-2020117794-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-10 | — | — | US | disclosed |
| WO-2018013430-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193038-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | HAVCR2, ZC3HAV1, CD4 | MCL1 1893/4885BCL2 3644/4885MDM2 4712/4885 |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | C9, C1R, C1S | MCL1 2544/4885BCL2 2702/4885MDM2 2955/4885 |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | C9, C1R, C1S | MCL1 2544/4885BCL2 2702/4885MDM2 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.